SCHEMBL17548459

SCHEMBL17548459

Cc1ccc(CSc2nc(C)c(C)c(Cl)n2)cc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.41
GAA P10253 2/20 0.41
GFER P55789 2/20 0.41
L3MBTL1 Q9Y468 5/20 0.41
LMNA P02545 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NPC1 O15118 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6391680 0.75 CYP1A2 (0.43) HTTGAAL3MBTL1LMNASMN1; SMN2
SCHEMBL6947272 0.70 ALDH1A1 (0.54) HTTGAALMNASMN1; SMN2MAPT
SCHEMBL6635668 0.70 RAB9A (0.43) HTTL3MBTL1LMNASMN1; SMN2MAPT
SCHEMBL8136440 0.69 HTT (0.40) HTTL3MBTL1LMNASMN1; SMN2MAPT
SCHEMBL17548458 0.69 HPGD (0.69) HTTGFERLMNAMAPTMEN1
SCHEMBL16019754 0.67 ALDH1A1 (0.45) HTTGAAL3MBTL1LMNASMN1; SMN2
Ammonia Solution, Strong SCHEMBL20610130 0.66 RAB9A (0.59) HTTGAAL3MBTL1SMN1; SMN2MAPT
SCHEMBL10389669 0.66 L3MBTL1 (0.58) HTTGAAL3MBTL1LMNASMN1; SMN2
SCHEMBL18656173 0.65 CYP1A2 (0.46) HTTGAAL3MBTL1LMNAMAPT
SCHEMBL98665 0.65 RAB9A (0.50) GAAL3MBTL1LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170362185-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE TES PHARMA S.R.L. (IT) 2017-12-21 US disclosed
US-9708272-B2 Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase TES PHARMA S.R.L. (IT) 2017-07-18 US disclosed
US-20160060226-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE TES PHARMA S.R.L. (IT) 2016-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060226-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE ACMSD, GLS, ALDH7A1 HTT 1861/4885GAA 127/4885GFER 596/4885
US-20170362185-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE ACMSD, GLS, ALDH7A1 HTT 1861/4885GAA 127/4885GFER 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.